Form 4: Aardvark Therapeutics CFO Nelson Sun Granted Significant Stock Options

Aardvark Therapeutics, Inc. Chief Financial Officer Nelson Sun was granted 209,826 stock options with an exercise price of $11.29, vesting over four years.

Summary

• Nelson Sun, the Chief Financial Officer of Aardvark Therapeutics, Inc. (AARD), was granted 209,826 stock options.
• The transaction date for this grant was June 11, 2025.
• The exercise price for these stock options is $11.29 per share.
• The options have an expiration date of June 11, 2035.
• The vesting schedule for these options is structured such that 1/4th of the shares will vest on June 11, 2026.
• Following the initial vesting, 1/48th of the shares will vest in monthly installments thereafter.
• Vesting is contingent upon Mr. Sun's continuous service to the company through each vesting date.
• Following this transaction, Nelson Sun beneficially owns 209,826 derivative securities directly.

Sentiment

Score: 6

Explanation: The sentiment is slightly positive as the grant of stock options aligns the CFO's interests with shareholders and is a standard practice for executive retention and motivation.

Positives

• The grant of stock options aligns the Chief Financial Officer's financial interests with those of the shareholders, incentivizing long-term performance and value creation.
• Equity compensation is a standard practice for retaining and motivating key executives.

Future Outlook

The vesting schedule for the stock options, extending through monthly installments after June 11, 2026, indicates an expectation of Nelson Sun's continued service to Aardvark Therapeutics, Inc. for the foreseeable future.

Industry Context

The granting of stock options to a Chief Financial Officer is a common form of executive compensation in the biotechnology and pharmaceutical industries, designed to align management incentives with long-term shareholder value and retain key talent.

Stakeholder Impact

• Shareholders: The grant aims to align the CFO's performance with shareholder interests, potentially leading to increased long-term value.
• Employees (CFO): Provides a significant equity incentive, enhancing retention and motivation for the Chief Financial Officer.

Next Steps

• Continued vesting of the stock options according to the specified schedule, contingent on continuous service.

Key Dates

Keywords

Aardvark Therapeutics, Nelson Sun, Stock Option, Equity Compensation, CFO, SEC Form 4, Insider Transaction, AARD